Overview

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This open-label, multicenter study is designed to investigate the clinical utility and safety of pramlintide treatment in subjects with type 1 and type 2 diabetes who are failing to achieve the desired level of glycemic control using insulin therapy.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Islet Amyloid Polypeptide
Pramlintide